# The Addition of Pembrolizumab to Postoperative Radiotherapy in Cutaneous Squamous Cell Cancer of the Head and Neck

> **NCT03057613** · PHASE2 · COMPLETED · sponsor: **Case Comprehensive Cancer Center** · enrollment: 18 (actual)

## Conditions studied

- Squamous Cell Carcinoma of the Head and Neck

## Interventions

- **DRUG:** Pembrolizumab
- **RADIATION:** IMRT 60-66Gy

## Key facts

- **NCT ID:** NCT03057613
- **Lead sponsor:** Case Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-10
- **Primary completion:** 2020-06-26
- **Final completion:** 2020-09-09
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2022-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03057613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03057613, "The Addition of Pembrolizumab to Postoperative Radiotherapy in Cutaneous Squamous Cell Cancer of the Head and Neck". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03057613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*